Skip to content

Repligen RGEN Cash Provided by (Used in) Financing Activity, Including Discontinued Operation

Cash Provided by (Used in) Financing Activity, Including Discontinued Operation at other companies

Charles River Laboratories logo
Charles River LaboratoriesCRL
$347.72M+430%
Revvity logo
RevvityRVTY
Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
International Flavors & Fragrances logo
International Flavors & FragrancesIFF
GLW
CorningGLW

Other financials

Income statement

See full
Revenue$194.3M+14.8%
Gross profit$108.3M+18.5%
Operating income$15.9M+142%
Net income$8.3M+42.9%
EPS (diluted)$0.15+50.0%

Balance sheet

See full
Cash & equivalents$582.7M-16.4%
Total debt$687.6M+346%
Total equity$2.1B+6.0%
Total assets$2.9B+2.8%

Cash flow

See full
Operating cash flow$28.3M+88.6%
CapEx$4.7M+32.2%
Free cash flow$23.6M+106%

Valuation

See full
Market cap$7.45B-7.1%
Enterprise value$7.55B+2.1%
P/E144.9×
P/S10.1×-0.1×

Profitability

See full
Gross margin49.5%+2.7pp
Operating margin1.5%-14.0pp
Net margin17.1%-3.7pp
FCF margin21.2%+6.1pp

Returns & leverage

See full
Return on equity2.5%+1.9pp
Debt / equity0.3×+0.2×
Current ratio9.2×+2.4×

Where this comes from

Reported directly by Repligen in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The official record: Repligen’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Repligen's cash provided by (used in) financing activity, including discontinued operation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Repligen's cash provided by (used in) financing activity, including discontinued operation?
Repligen (RGEN) reported cash provided by (used in) financing activity, including discontinued operation of -$5.54M in Q1 2026.
How has Repligen's cash provided by (used in) financing activity, including discontinued operation changed year-over-year?
Repligen's cash provided by (used in) financing activity, including discontinued operation decreased by 10.2% year-over-year, from -$5.03M to -$5.54M.
What is the long-term trend for Repligen's cash provided by (used in) financing activity, including discontinued operation?
Over 3 years (2022 to 2025), Repligen's cash provided by (used in) financing activity, including discontinued operation has grown at a 1.8% compound annual growth rate (CAGR), from -$14.59M to -$15.4M.
What does cash provided by (used in) financing activity, including discontinued operation mean?
This metric measures the net cash flow between the company and its capital providers, including proceeds from debt or equity issuance and payments for dividends or share repurchases. It highlights how the company finances its operations and returns value to shareholders.